News Articles
Browse our entire archive of news articles, spotlight interviews, and other editorial pieces in one place.
Filters
MindMed Collaborators Initiate Phase 1 Comparative PK/PD Trial of R-, S- and Racemic MDMA
Mind Medicine (MindMed)
Universal Ibogaine Undertaking Offering of Convertible Debt Securities and Common Shares
Universal Ibogaine
Lobe Sciences Announces the Expansion of its Patent Portfolio with International Filings
Lobe Sciences
Tryp Therapeutics Announces Publication of International PCT Patent Application for the Intravenous Administration of Psilocin and Psilocybin
Tryp Therapeutics
Reunion Neuroscience to Participate in the Cantor Neurology & Psychiatry Conference
Reunion Neuroscience
Revitalist Non-Profit, “Community Change Foundation”, Receives $1M Grant to Address Adolescent Mental Health and School Violence
Revitalist Lifestyle and Wellness
Core One Labs Announces Breakthrough with Proprietary Isolation and Purification Method of Psilocybin from Mushrooms; Prepares Patent Application
Core One Labs Inc.
Psychedelic Weekly Headlines | September 30
Silo Wellness
Tryp Therapeutics
Psyence Group
Cybin Inc.
ATAI Life Sciences
Nova Mentis Psilocybin Microdose Capsule Formulation to be Submitted in Health Canada Phase 2A Clinical Trial Application
Nova Mentis Life Science
Wellbeing Digital to Participate in the Cantor Fitzgerald Symposium on Mental Health Clinics
Wellbeing Digital Sciences
Reunion Neuroscience Inc. Appoints Greg Mayes as President and Chief Executive Officer
Reunion Neuroscience
BLACKHAWK's Mindbio Announces Phase 2A/B Clinical Trials Microdosing LSD in Major Depressive Disorder Submitted for Ethics & Regulatory Approval
MindBio Therapeutics
atai Life Sciences Announces Initiation of Phase 1 Trial for its MDMA Derivative, EMP-01
ATAI Life Sciences
MindMed Announces Pricing of Public Offering of Common Shares and Warrants
Mind Medicine (MindMed)
MindMed Announces Proposed Public Offering of Common Shares
Mind Medicine (MindMed)
Get the Headlines & Market Updates
Be the first to see new company features, exclusive interviews and breaking news. Subscribe now.